MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


SourceBio swings to profit as Covid-19 testing boosts sales

StockMarketWire.com

Laboratory services provider SourceBio International, which listed on AIM in October, swung to a full-year profit as its revenue more than doubled on the back of Covid-19 testing services.

Pre-tax profit for the year through December amounted to £2.8 million, compared to a year-on-year loss of £8.0 million.

Revenue jumped to £50.7 million, up from £21.2 million.

SourceBio had last May established a new business unit, infectious disease testing, with the launch of Covid-19 testing services, through high-volume laboratory based testing.

'The results have been dominated by the provision of Covid-19 testing services and, accepting the ongoing impact of the Covid-19 pandemic, the board remains pleased with performance across all areas of the business,' chief executive Jay LeCoque said.

'The group remains strongly capitalised with no borrowings, which positions us well to deliver further aggressive growth in 2021.'

At 9:03am: (LON:SBI) share price was 0p at 171p


Story provided by StockMarketWire.com